Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model

被引:40
作者
Cha, R
Rybak, MJ
机构
[1] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Dept Pharm Practice, Antiinfect Res Lab, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Detroit, MI 48201 USA
关键词
bacteria; resistance; cyclic lipopeptides; antimicrobials; albumin;
D O I
10.1093/jac/dkh259
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: Daptomycin exhibits bactericidal activity against clinically significant Gram-positive bacteria despite being highly bound to human proteins. Evaluations characterizing the effect of protein on daptomycin pharmacodynamics are warranted. Methods: We utilized an in vitro pharmacodynamic model to simulate daptomycin regimens of 6 mg/kg/day under controlled conditions of pH, calcium and/or protein. Free concentrations were simulated in broth, whereas total concentrations were simulated in broth supplemented with human albumin. Bacterial density was profiled over 48 h for two methicillin-resistant Staphylococcus aureus (MRSA) and two vancomycin-resistant Enterococcus faecium (VREF) clinical isolates. Results: Daptomycin exhibited bactericidal activity against both MRSA isolates, with time to 99.9% killing occurring at 0.5 h and 8 h in broth and in albumin-supplemented broth, respectively. Initial kill was observed against both VREF isolates followed by regrowth. There was no statistical difference (P>0.05) in extent of bacterial kill at 24 or 48 h between the different media. Conclusions: Although delayed, the extent of kill for daptomycin was unaltered against all isolates in albumin-supplemented broth. Further antimicrobial studies that incorporate protein are warranted to assess the influence of protein in the pharmacodynamic evaluation of antimicrobials.
引用
收藏
页码:259 / 262
页数:4
相关论文
共 10 条
[1]   In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model [J].
Akins, RL ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) :1925-1929
[2]   Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations [J].
Akins, RL ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :454-459
[3]   COMPARATIVE EFFECT OF PROTEIN-BINDING ON THE KILLING ACTIVITIES OF TEICOPLANIN AND VANCOMYCIN [J].
BAILEY, EM ;
RYBAK, MJ ;
KAATZ, GW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (06) :1089-1092
[4]  
BRIER GL, 1989, 29 INT C ANT AG CHEM, P329
[5]   Daptomycin dose-effect relationship against resistant gram-positive organisms [J].
Cha, R ;
Grucz, RG ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1598-1603
[6]   HUMAN SERUM ENHANCES THE POSTANTIBIOTIC EFFECT OF FLUOROQUINOLONES AGAINST STAPHYLOCOCCUS-AUREUS [J].
DAVIDSON, RJ ;
ZHANEL, GG ;
PHILLIPS, R ;
HOBAN, DJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (06) :1261-1263
[7]   INVITRO PHARMACODYNAMIC EFFECTS OF CONCENTRATION, PH, AND GROWTH-PHASE ON SERUM BACTERICIDAL ACTIVITIES OF DAPTOMYCIN AND VANCOMYCIN [J].
LAMP, KC ;
RYBAK, MJ ;
BAILEY, EM ;
KAATZ, GW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (12) :2709-2714
[8]   Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection [J].
Louie, A ;
Kaw, P ;
Liu, WG ;
Jumbe, N ;
Miller, MH ;
Drusano, GL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :845-851
[9]   EFFECT OF HUMAN SERUM ON KILLING ACTIVITY OF VANCOMYCIN AND TEICOPLANIN AGAINST STAPHYLOCOCCUS-AUREUS [J].
STANLEY, D ;
MCGRATH, BJ ;
LAMP, KC ;
RYBAK, MJ .
PHARMACOTHERAPY, 1994, 14 (01) :35-39
[10]   Development of daptomycin for Gram-positive infections [J].
Tally, FP ;
DeBruin, MF .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (04) :523-526